{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-023842","form_type":"8-K","ticker":"KOD","cik":"0001468748","company_name":"Kodiak Sciences Inc.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.759987+00:00","generated_at":"2026-06-22T01:06:16.622615+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Kodiak Sciences Q3 net loss $77M; cash $537M; Ph3 trials on track for 2023 readouts","bullets":["Net loss of $77.0M ($1.47/sh) vs $67.5M ($1.30) in Q3 2021; increase driven by stock-based compensation.","Cash, cash equivalents and marketable securities of $537.4M; includes $2.5M unrealized loss from interest rates.","R&D expenses $61.7M (up from $56.0M) and G&A $17.8M (up from $11.5M) both primarily due to non-cash stock comp.","Four Phase 3 trials (GLEAM/GLIMMER DME, DAYLIGHT wet AMD, GLOW NPDR) expected to report topline data in 2023.","KSI-501 IND filing on track for Q4 2022; Phase 1 study expected to begin early 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-023842","json":"https://secwatch.observer/filing/0000950170-22-023842.json","markdown":"https://secwatch.observer/filing/0000950170-22-023842.md","text":"https://secwatch.observer/filing/0000950170-22-023842.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1468748/000095017022023842/0000950170-22-023842-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1468748/000095017022023842/kod-20221109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T01:06:16.622615+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8010b367393cb0a125353f212ed398700555d8e3","claim":"Kodiak Sciences Inc. reported third quarter of 2022 results: net income $77.0 million, or $1.47 per share.","evidence_excerpt":"Kodiak Sciences Inc. (the “Company”) issued a press release reporting the Company’s financial results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1468748/000095017022023842/0000950170-22-023842-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter of 2022"},{"label":"Net income","value":"$77.0 million, or $1.47 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}